BeiGene, Financials
ONC Stock | 224.99 0.00 0.00% |
Operating Margin | Profit Margin | Short Ratio 3.97 | EPS Estimate Current Year (5.63) | Return On Equity |
The essential information of the day-to-day investment outlook for BeiGene, includes many different criteria found on its balance sheet. An individual investor should monitor BeiGene,'s cash flow, debt, and profitability to accurately make informed decisions on whether to invest in BeiGene,.
Net Income |
|
BeiGene, | Select Account or Indicator |
Please note, the presentation of BeiGene,'s financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, BeiGene,'s management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of BeiGene,'s management manipulating its earnings.
BeiGene, Stock Summary
BeiGene, competes with CECO Environmental, Gfl Environmental, Eastman Chemical, Axalta Coating, and Nippon Steel. BeiGene, is entity of United States. It is traded as Stock on NASDAQ exchange.Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
Instrument | USA Stock View All |
Exchange | NASDAQ Exchange |
CUSIP | 07725L102 |
Older Symbol | BGNE |
Location | Cayman Islands |
Business Address | 94 Solaris Avenue, |
Sector | Biotechnology |
Industry | Health Care |
Benchmark | Dow Jones Industrial |
Website | www.beigene.com |
Phone | 345 949 4123 |
BeiGene, Key Financial Ratios
Revenue | 2.46 B | ||||
Gross Profit | 19.67 B | ||||
Net Income | (881.71 M) | ||||
Total Asset | 5.81 B | ||||
Retained Earnings | (7.96 B) |
BeiGene, Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining BeiGene,'s current stock value. Our valuation model uses many indicators to compare BeiGene, value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across BeiGene, competition to find correlations between indicators driving BeiGene,'s intrinsic value. More Info.BeiGene, is considered to be number one stock in return on equity category among its peers. It also is considered to be number one stock in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the BeiGene,'s earnings, one of the primary drivers of an investment's value.BeiGene, Systematic Risk
BeiGene,'s systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. BeiGene, volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was thirty with a total number of output elements of thirty-one. The Beta measures systematic risk based on how returns on BeiGene, correlated with the market. If Beta is less than 0 BeiGene, generally moves in the opposite direction as compared to the market. If BeiGene, Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one BeiGene, is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of BeiGene, is generally in the same direction as the market. If Beta > 1 BeiGene, moves generally in the same direction as, but more than the movement of the benchmark.
BeiGene, February 1, 2025 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of BeiGene, help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of BeiGene,. We use our internally-developed statistical techniques to arrive at the intrinsic value of BeiGene, based on widely used predictive technical indicators. In general, we focus on analyzing BeiGene, Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build BeiGene,'s daily price indicators and compare them against related drivers.
Downside Deviation | 2.86 | |||
Information Ratio | 0.0088 | |||
Maximum Drawdown | 17.0 | |||
Value At Risk | (4.30) | |||
Potential Upside | 4.29 |
Complementary Tools for BeiGene, Stock analysis
When running BeiGene,'s price analysis, check to measure BeiGene,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BeiGene, is operating at the current time. Most of BeiGene,'s value examination focuses on studying past and present price action to predict the probability of BeiGene,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BeiGene,'s price. Additionally, you may evaluate how the addition of BeiGene, to your portfolios can decrease your overall portfolio volatility.
AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
Commodity Channel Use Commodity Channel Index to analyze current equity momentum |